Clear Cell Renal Cell Carcinoma Molecular Variations in Non-Hispanic White and Hispanic Patients

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Apr 21

PMID 37081700

Authors

Ken Batai

Yuliang Chen

Brenna A Rheinheimer

Amit Arora

Ritu Pandey

Ronald L Heimark

Erika R Bracamonte

Nathan A Ellis

Benjamin R Lee

Affiliations

Soon will be listed here.

Abstract

Background: The United States is becoming increasingly diverse, but few molecular studies have assessed the progression of clear cell renal cell carcinoma (ccRCC) in diverse patient populations. This study examined ccRCC molecular variations in non-Hispanic White (NHW) and Hispanic patients and their effect on the association of gene expression with high-grade (Grade 3 or 4) ccRCC and overall mortality.

Methods: A total of 156 patients were included in VHL sequencing and/or TempO-Seq analysis. DESeq2 was used to identify the genes associated with high-grade ccRCC. Logistic regression analysis was performed to assess whether race and ethnicity was associated with high/moderate impact VHL somatic mutations and the ccA/ccB subtype. Cox regression analysis was performed to assess association of molecular subtype and gene expression with overall mortality.

Results: NHWs had moderate or high impact mutations in the VHL gene at a higher frequency than Hispanics (40.2% vs. 27.4%), while Hispanics had a higher frequency of the ccA subtype than NHWs (61.9% vs. 45.8%). ccA was more common in patients with BMI≥35 (65.2%) than in those with BMI < 25 (45.0%). There were 11 differentially expressed genes between high- and low-grade tumors. The Haptoglobin (HP) gene was most significantly overexpressed in high- compared to low-grade ccRCC in all samples (p-adj = 1.7 × 10 ). When stratified by subtype, the 11 genes were significantly differentially expressed in the ccB subtype, but none of them were significant after adjusting for multiple testing in ccA. Finally, patients with the ccB subtype had a significantly increased risk of overall mortality (HR 4.87; p = 0.01) compared to patients with ccA, and patients with high HP expression and ccB, had a significantly increased risk of mortality compared to those with low HP expression and ccA (HR 6.45, p = 0.04).

Conclusion: This study reports ccRCC molecular variations in Hispanic patients who were previously underrepresented.

Citing Articles

A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma.

Kumar S, Khandekar N, Dani K, Bhatt S, Duddalwar V, DSouza A Oncology. 2024; :1-10.

PMID: 39250899 PMC: 11890214. DOI: 10.1159/000541370.

Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients.

Batai K, Chen Y, Rheinheimer B, Arora A, Pandey R, Heimark R Cancer Med. 2023; 12(11):12792-12801.

PMID: 37081700 PMC: 10278477. DOI: 10.1002/cam4.5929.

References

Valencia C, Asmar S, Hsu C, Gachupin F, Wong A, Chipollini J . Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data. Cancers (Basel). 2021; 13(5). PMC: 7956712. DOI: 10.3390/cancers13050990. View

Cruz A, Dickerson F, Pulling K, Garcia K, Gachupin F, Hsu C . Impacts of Neighborhood Characteristics and Surgical Treatment Disparities on Overall Mortality in Stage I Renal Cell Carcinoma Patients. Int J Environ Res Public Health. 2022; 19(4). PMC: 8872003. DOI: 10.3390/ijerph19042050. View

Liu W, Zheng S, Na R, Wei L, Sun J, Gallagher J . Distinct Genomic Alterations in Prostate Tumors Derived from African American Men. Mol Cancer Res. 2020; 18(12):1815-1824. DOI: 10.1158/1541-7786.MCR-20-0648. View

Callahan C, Moore L, Lenz P, Linehan W, Nickerson M, Rothman N . Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. Eur Urol. 2019; 75(5):882-884. PMC: 8495471. DOI: 10.1016/j.eururo.2019.01.001. View

Moore L, Nickerson M, Brennan P, Toro J, Jaeger E, Rinsky J . Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011; 7(10):e1002312. PMC: 3192834. DOI: 10.1371/journal.pgen.1002312. View

Purdue M, Rhee J, Moore L, Gao X, Sun X, Kirk E . Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma. Int J Cancer. 2021; 149(7):1448-1454. PMC: 8628648. DOI: 10.1002/ijc.33701. View

Batai K, Bergersen A, Price E, Hynes K, Ellis N, Lee B . Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine. Clin Genitourin Cancer. 2018; 16(3):e535-e541. DOI: 10.1016/j.clgc.2018.01.006. View

Callahan C, Hofmann J, Corley D, Zhao W, Shuch B, Chow W . Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis. Cancer Epidemiol. 2018; 56:31-37. PMC: 6151870. DOI: 10.1016/j.canep.2018.07.002. View

Brooks S, Brannon A, Parker J, Fisher J, Sen O, Kattan M . ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014; 66(1):77-84. PMC: 4058355. DOI: 10.1016/j.eururo.2014.02.035. View

10.

Gachupin F, Lee B, Chipollini J, Pulling K, Cruz A, Wong A . Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona. Int J Environ Res Public Health. 2022; 19(3). PMC: 8834853. DOI: 10.3390/ijerph19031185. View

11.

Pflugfelder A, Yong X, Jagirdar K, Eigentler T, Soyer H, Sturm R . Genome-Wide Association Study Suggests the Variant rs7551288*A within the Gene Is Associated with Poor Overall Survival in Melanoma Patients. Cancers (Basel). 2022; 14(10). PMC: 9139953. DOI: 10.3390/cancers14102410. View

12.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

13.

Aldrighetti C, Niemierko A, Van Allen E, Willers H, Kamran S . Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open. 2021; 4(11):e2133205. PMC: 8576580. DOI: 10.1001/jamanetworkopen.2021.33205. View

14.

Li H, Durbin R . Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010; 26(5):589-95. PMC: 2828108. DOI: 10.1093/bioinformatics/btp698. View

15.

Riscal R, Bull C, Mesaros C, Finan J, Carens M, Ho E . Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma. Cancer Discov. 2021; 11(12):3106-3125. PMC: 8741905. DOI: 10.1158/2159-8290.CD-21-0211. View

16.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

17.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

18.

Tai C, Lin Y, Teng T, Lin P, Tu S, Chou C . Haptoglobin expression correlates with tumor differentiation and five-year overall survival rate in hepatocellular carcinoma. PLoS One. 2017; 12(2):e0171269. PMC: 5291462. DOI: 10.1371/journal.pone.0171269. View

19.

Minovic I, Eisenga M, Riphagen I, van den Berg E, Kootstra-Ros J, Frenay A . Circulating Haptoglobin and Metabolic Syndrome in Renal Transplant Recipients. Sci Rep. 2017; 7(1):14264. PMC: 5660219. DOI: 10.1038/s41598-017-14302-2. View

20.

Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J . Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017; 3(12):1654-1662. PMC: 5671371. DOI: 10.1001/jamaoncol.2017.0595. View